Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATChEz: Pazopanib followed by Everolimus in RCC
NCT01545817Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2012
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of everolimus in renal cell carcinoma (RCC), sponsored by Novartis. Started Apr 2012; status: terminated.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01545817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01545817.